Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

OGN - Organon & Co. So'nggi Yangiliklar | Finranks

Home

OGN

O

Organon & Co. (OGN)

NYQ – Real vaqt narxi. Valyuta: USD

5.84

-0.21 (-3.47%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

5.88

+0.04 (0.68%)

Bozordan keyin: Mar 27, 2026, 7:50 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights

Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Organon (OGN) closed at $5.84, marking a -3.47% move from the previous day.

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Sio initiated a new OGN position in the fourth quarter, buying up 3,421,765 shares. The quarter-end position value increased by $24.53 million as a result.

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about ‌a potential risk of seizures.

Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know

Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know

Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition.

Videolar

No Data

There is no data to display

Press-relizlar

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition.

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Dru.